VTVT vTv Therapeutics Inc.
$25.72▼ -0.83%
Healthcare
Other
Volume 11.1K
Avg Volume (10D) 19.6K
Key Metrics & Fundamentals
Market Cap
$101.70M
P/E Ratio
–
Div Yield
0.00%
52W Range
19.80 - 44.00
% vs 50 MA
-16.19%
% vs 200 MA
-23.63%
RSI-14
32.7
MACD Histogram
-0.2500
Beta (1Y vs SPY)
1.11
Free Cash Flow
-$11.44M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$13.93M
COGS
–
Operating Exp
$13.93M
Operating Income
-$13.93M
EBIT
-$13.93M
Pretax Income
-$13.05M
Net Income
-$13.05M
EPS (Diluted)
-1.05
Price & Volume History
Loading chart…
Recent News
vTv Therapeutics Announces First Participant Randomized in Phase 2a Pilot Study Evaluating Cadisegliatin in Individuals with Type 1 Diabetes (T1D) Using Hybrid Closed-Loop (HCL) Insulin Delivery Systems
GlobeNewswire · Oct 27, 2026 8:00 AM ET
vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia
MarketBeat · Oct 20, 2026 8:02 PM ET
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
GlobeNewswire · Oct 15, 2026 3:30 AM ET
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
GlobeNewswire · Oct 10, 2026 8:00 AM ET
vTv Therapeutics stock jumps on FDA orphan drug status
Investing.com · Oct 8, 2026 9:43 AM ET
VTv Therapeutics Gets FDA Orphan Drug Designation for Sickle Cell Candidate
MT Newswires · Oct 7, 2026 4:53 PM ET
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
GlobeNewswire · Oct 7, 2026 4:01 PM ET
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
GlobeNewswire · Oct 6, 2026 8:00 AM ET
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
GlobeNewswire · Oct 5, 2026 8:00 AM ET
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · Sep 15, 2026 4:05 PM ET
Financial Overview - Income Statement
Quarterly
Mar 2026
See VTVT's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.